Neuigkeiten

CryoCath Closes Exercise of Over-Allotment Option

This news release is intended for distribution in Canada only and is not intended for distribution to United States newswire services or dissemination in the United States.

Montreal, Canada, June 6, 2008 - CryoCath Technologies Inc. (TSX: CYT), today announced that it has closed the previously announced partial exercise by the underwriters of the over-allotment option granted to them in connection with CryoCath’s recent bought deal offering of Common Shares. Pursuant to the exercise of the over-allotment option, CryoCath has issued 138,100 Common Shares at the offering price of $4.15 per Common Share, for additional total gross proceeds to CryoCath of $573,115. The total gross proceeds to CryoCath from the bought deal offering, including the gross proceeds from the exercise of the over-allotment option, is $17,961,615. The syndicate of underwriters for the offering was led by GMP Securities L.P. and included Blackmont Capital Inc. and Macquarie Capital Markets Canada Ltd.

The net proceeds of the offering, including the net proceeds from the over-allotment portion thereof, will be used (i) to fund additional research, development and commercialization of our products, including the Company’s pivotal clinical trial aimed at obtaining U.S. approval for the Arctic Front system to treat Atrial Fibrillation (AFib), (ii) to expand marketing efforts in Europe and in the U.S., and (iii) for general corporate (including repaying certain indebtedness) and working capital purposes.

THE COMMON SHARES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS ABSENT U.S. REGISTRATION OR AN APPLICABLE EXEMPTION FROM U.S. REGISTRATION REQUIREMENTS.

About Medtronic CryoCath

CryoCath – www.cryocath.com – is a medical technology company that leads the world in cryotherapy products to treat cardiac arrhythmias. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.

This press release includes “forward looking statements” that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath’s annual report available at www.sedar.com under the heading Risks and Uncertainties in the Management’s Discussion and Analysis section.

For further information, please contact:

Ross Marshall
Phone: 416 815 0700 ext. 238
E-mail: rmarshall@equicomgroup.com